This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too. Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nur
Food-as-medicine programs that address food insecurity and diet-related chronic diseases have drawn widespread attention from policymakers , payers, and health care providers. But what is the evidence that such programs work as intended? Some research suggests that food as medicine can improve health and lower health care costs, but until now there has been little evidence from randomized clinical trials.
Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. This application paves the way for Phase I trial of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC) who have not responded to Bacillus Calmette-Guérin (BCG) therapy, making it globally the second saRNA drug to advance into the clinical stage, says GlobalData.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier. The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sle
AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharma company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. The proposed acquisition will add to AstraZeneca’s pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, a potential new treatment for multiple myeloma, as well as
LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice? Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them.
275
275
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice? Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them.
Informa Markets in India recently organised the CPHI & PMEC India 2023 at the India Expo Centre in Greater Noida, Delhi-NCR. A statement from Informa markets informed, “As the largest and most exhaustive pharma industry gathering in South Asia, CPHI and PMEC India expo, drew an overwhelming positive response, attracting over 48,000 attendees from 120+ countries in a vast 100,000 sq m exhibition space.
It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules. Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024: Lobbying power of AI, software-enabled devices Medtech lobby AdvaMed announced earlier this month that the major med
Industry leader Sameer Joshi, COO & CCO, Cepham Inc., US, moderates an intriguing conversation between Len Monheit, CEO, Trust Transparency Center, and Jon Benninger, Vice President, Informa Markets US. The discussion centers on ‘Exploring the Critical Need for Transparency in the Nutraceutical Supply Chain: A Deep Dive into the Importance of Source Verification, Manufacturing Processes, and Regulatory Compliance to Ensure Product Quality and Consumer Safety.
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer. RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals , which pair the tumor-killing power of radiation with the precision of targeted cancer therapies.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The number of approved gene therapies for the treatment of monogenetic disorders and diseases has increased in recent years, reflecting the field’s rapid advances and the development of revolutionary new technologies and techniques. The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population.
Exploring the powerful collaborations between scientists, investors, and the medical community in finding breakthrough treatments for major diseases, and the notion of 'healthspan'
Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market. The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
In the first of a five-part festive instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Advarra’s chief product officer, Elisa Cascade, about the reasons behind increasing burdens on clinical research sites over the last five years.
As an update to our previous report , Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced the successful completion of the transition of the acquired biosimilars business in approximately 120 countries, a year ahead of schedule. On December 18, 2023, IAVI, a global nonprofit scientific research organization, and Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, announced that the Bill & Melinda Gates Foundation has awarded IAVI $55 million to conduct a Phase IIb t
On December 15, 2023, Vertex announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs… The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Aurobindo Pharma’s wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Noxafil Injection, 300 mg/16.7 mL (18 mg/mL), of Merck Sharp & Dohme LLC (Merck).
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents… The post New patent for Blueprint Medicines drug AYVAKIT appeared first on DrugPatentWatch - Make Better Decisions.
A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two or more systemic treatments earlier. The regulatory agency accepted the BLA, with a decision on the drug approval anticipated on 26 June 2024. The latest development comes after the FDA awarded breakthrough therapy designation for patritumab deruxtecan in December 2021.
Annual Drug Patent Expirations for COREG+CR Coreg Cr is a drug marketed by Woodward and is included in one NDA. It is available from four suppliers. There are two patents… The post New patent expiration for Woodward drug COREG CR appeared first on DrugPatentWatch - Make Better Decisions.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Registrations, Starting Soon! WORKSHOP International Pharma Marketing Career Development Workshop Session 1: Foundation & Industry Understanding January 21, 2024 11:30 AM - 12:30 PM Days Hours Minutes Seconds What will you learn? As you will join us for ‘Session 01: Foundation and Industry Understanding’, we shall explore the educational pathways and qualifications necessary to succeed in the pharmaceutical industry.
Introduction Burns are characterized as First degree - Red/painful, minor swelling. Second degree - Thicker, very painful, produce blisters. Third degree - Damage to all layers of skin, appears white or charred. The Need of Referral Burns from chemical or electricity exposure or in immunosuppressed patients should be referred for emergency medical care.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content